That's exactly what the biotech Bluebird Bio is suggesting for its cutting-edge, experimental gene therapy, LentiGlobin, which is intended as a one-time treatment for the rare blood disorder beta thalassemia. Installment plans are used for big-ticket items like dishwashers and TVs - and now, for medical treatments? Bluebird CEO Nick Leschly told Business Insider the inside story of how the plan came about and what challenges it could face.The company hasn't put out a price tag for the experimental product, which hasn't yet been approved, but capped it at $2.1 million a treatment.Biotech company Bluebird Bio proposed a five-year installment plan for its pricey gene therapy at a major healthcare conference on Tuesday.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |